Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SFDA to Withdraw One Parkinson's Drug From Market (China)

This article was originally published in PharmAsia News

Executive Summary

China's State Food and Drug Administration (SFDA) has announced it will phase out approval and distribution for Parkinson's disease drug Permax because it carries a serious risk of heart damage. In January this year The New England Journal of Medicine published two studies confirming a link between Permax and heart valve damage and disease. China will halt sale and use of this drug by Jan. 1, 2008, and today will phase out use by current Permax users because sudden cessation could jeopardize patients' health. Permax also is known as Pergolide Mesylate. The United States, Korea, and others already have halted sales. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts